Commitment to Impact: Strengthening Measurement of Industry-Led Access-to-Medicines Programs

The pharmaceutical industry has confirmed its commitment to partnering with other actors to achieve the Sustainable Development Goals. There is a unique opportunity for the industry, academia, and other global health stakeholders to come together and strengthen institutions for measuring industry-led access-to-medicines (IL-AtM) programs. We propose five critical elements of the institutional context for measurement of IL-AtM programs that should be strengthened: (1) standards for measurement; (2) platforms for learning; (3) systems for transparency; (4) mechanisms for accountability; and (5) investments for sustainability. Evidence about what works would help direct future investments toward more effective programs, to the benefit of industry and society.